SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 29, 2018-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will join the Pancreatic Cancer Action Network (PanCAN) PurpleStride San Francisco on Sunday, June 3, in memory of Five Prime employee Melinda Van Roey, who passed away after her battle against pancreatic cancer.
PurpleStride San Francisco, the walk to end pancreatic cancer, is one of 55 PurpleStride events across the country, bringing together survivors, families, researchers and caregivers dedicated to changing the future of pancreatic cancer. PurpleStride is PanCAN’s most powerful vehicle for disease awareness and fundraising efforts.
“There is a tremendous unmet need for patients with pancreatic cancer,” said Aron Knickerbocker, chief executive officer of Five Prime. “As we continue to advance therapeutic programs targeting this disease, we want to demonstrate our commitment to patients by supporting PanCAN’s efforts in the community. I am proud that our employees are devoted to making an impact on the lives of patients facing pancreatic cancer.”
Pancreatic cancer is the third leading cause of cancer-related death in the United States with a five-year survival rate of just 9 percent. In 2018, it is predicted that about 55,000 people in the US will be diagnosed with pancreatic cancer and about 44,000 people will die from this disease.
With those patients in mind, Five Prime employees and their families have united to support PanCAN’s urgent mission to save lives and double survival by 2020. The Company is also supporting the walk as a Bronze Sponsor.
To learn more about PanCAN, visit pancan.org.
About the Pancreatic Cancer Action Network (PanCAN)
The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world’s toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve patient outcomes today and to double survival by 2020.